Ladenburg Thalmann Maintains Buy on TG Therapeutics, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Matthew Kaplan has maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) and increased the price target from $39 to $40.
May 02, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ladenburg Thalmann analyst Matthew Kaplan reaffirmed a Buy rating on TG Therapeutics and raised the price target to $40.
The increase in price target by a reputable analyst suggests a positive outlook on TG Therapeutics' stock, likely leading to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100